摘要
无论是内源性还是获得性化疗耐药,都已成为神经胶质瘤治疗的主要障碍。众所周知,胶质瘤化疗耐药是由多种机制相互作用导致的。所以,充分了解化疗耐药的潜在机制,开发新的治疗靶点来克服耐药,对于改善胶质瘤患者的预后至关重要。令人振奋的是,越来越多的证据表明,长链非编码RNA(long non-coding RNA,lnc RNA)可以通过靶向作用各种调控机制来介导胶质瘤的发生发展和耐药性。本综述系统地阐述了lnc RNA在胶质瘤耐药调控中的分子机制,并讨论了lnc RNA作为胶质瘤耐药标志物和新型治疗靶点的潜在功能。旨在通过调节这些特定lnc RNA来逆转肿瘤细胞的化疗抗性,为胶质瘤耐药治疗开辟新的研究方向。
Either endogenous or acquired resistance to chemotherapy has become the main obstacles in the treatment of neuroglioma.As is well⁃known,glioma chemoresistance is caused by interaction of multiple mecha⁃nisms.Therefore,sufficient understanding of potential mechanism on chemoresistance and development of new treatment targets to eliminate chemoresistance are crucial to the prognosis improvement for glioma patients.It is inspiring that more and more evidence has indicated that long non⁃coding RNA(lncRNA)mediated occurrence,development and chemoresistance of glioma via targeting at various regulation mechanisms.This review has systemi⁃cally clarified the molecular mechanism of lncRNA in the regulation of glioma chemoresistance and has discussed the potential function of lncRNA as a marker of glioma chemoresistance and a novel treatment target.It aims at developing novel research direction for glioma chemoresistance treatment by regulating these specific lncRNAs to reverse chemoresistance of tumor cells.
作者
曾昭穆
牛双
姬焱鑫
温稀超
刘超
吴文松
郑克彬
ZENG Zhaomu;NIU Sh-uang;JI Yanxin;WEN Xichao;LIU Chao;WU Wensong;ZHENG Kebin(The Affiliated Hospital of Hebei University,Baoding 071000,China;Hebei University,Baoding 071000,China)
出处
《实用医学杂志》
CAS
北大核心
2022年第16期1998-2001,共4页
The Journal of Practical Medicine
基金
2019年政府资助临床医学优秀人才培养项目(编号:361007)
河北大学医学学科重点培育项目(编号:2020A11)
河北大学研究生创新资助项目(编号:HBU2021ss025)。
